| Previous Close | 13.77 |
| Open | 13.76 |
| Bid | 14.00 x 100 |
| Ask | 14.20 x 100 |
| Day's Range | 13.70 - 14.18 |
| 52 Week Range | 8.31 - 27.84 |
| Volume | 5,923,963 |
| Avg. Volume | 16,432,771 |
| Market Cap | 4.9B |
| Beta | -1.10 |
| PE Ratio (TTM) | -4.30 |
| EPS (TTM) | -3.27 |
| Earnings Date | N/A |
| Dividend & Yield | 0.00 (0.00%) |
| Ex-Dividend Date | 2010-11-10 |
| 1y Target Est | N/A |
- Benzinga•2 days ago
GlassHouse: NuVasive Using The 'Valeant Playbook' To Deceive Investors
Short seller GlassHouse Research has accused medical device company NuVasive, Inc. (NASDAQ: NUVA ) of “irregular accounting” practices and says the stock has more than 50 percent downside. In a new report, ...
- Barrons.com•3 days ago
Valeant Pharmaceuticals: Is A New Drug Approval On The Horizon?
H.C. Wainwright’s Raghuram Selvaraju predicts that Valeant Pharmaceuticals (VRX) could receive FDA approval this week for its experimental glaucoma drug Vyzulta. For those who are not familiar with the situation, in July 2016, Valeant announced that it had received a complete response letter from the FDA regarding Vyzulta. The letter highlighted concerns about Bausch & Lomb’s manufacturing facility in Tampa.
- Benzinga•3 days ago
What You Should Know About The Drug Approval Valeant Could Receive This Week
Amid “overstated” legal issues and in the aftermath of natural disaster, Valeant Pharmaceuticals Intl Inc (NYSE: VRX ) may profit from a positive catalyst this week, according to H.C. Wainwright & Co. ...
